Dexmedetomidine attenuates myocardial ischemia–reperfusion injury in hyperlipidemic rats by inhibiting inflammation, oxidative stress and NF‐κB
Chemical Biology & Drug Design · 2023
DOI: 10.1111/cbdd.14324 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2023. Verfasst von Weiwei Gao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The First Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Myocardial Reperfusion Injury, Dexmedetomidine, Reperfusion Injury. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
The present study was conducted to determine the protective effect of Dexmedetomidine (DEX) in myocardial ischemia–reperfusion injury in hyperlipidemic rats. Towards this, the effect of DEX was first evaluated on the infarct size and the histopathology of cardiac tissues using TTC and H and E staining, and it was found that DEX significantly improved the infarct size and architecture of the myocardial tissues following the I/R injury. DEX also showed significant improvement in various examined hemodynamic parameters (e.g., LVSP, and ± dp/dt max ) in a dose‐dependent manner. The lipid profile (LDL, VLDL, TC, TG, and HDL level) of the rats were also found significantly improved in DEX‐treated rats. The level of various pro‐inflammatory cytokines (IL‐1β, IL‐6, IL‐10, IL‐17, and TNF‐α), cardiac injury (CK, CK‐MB, Troponin I AST, ALT, and LDH), and oxidative stress (MDA, SOD, and GSH) biomarkers were also found to be restored near to the normal in DEX‐treated group. It has been found that DEX also significantly reduces apoptosis of rat cardiomyocytes. In western blot analysis, DEX showed a significant reduction in the activation of NF‐κB. In conclusion, our study demonstrated the protective effect of Dexmedetomidine in myocardial ischemia–reperfusion injury in hyperlipidemic rats possibly via amelioration of oxidative stress, and inflammation apoptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, The First Hospital of Hebei Medical University, Shijiazhuang, China.
- Operating Center, The First Hospital of Hebei Medical University, Shijiazhuang, China.
- Pharmacy Intravenous Admixture Services, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Zitieren
APA
Gao, W., Du, L., Li, N., Li, Y., Wu, J., Zhang, Z., & Chen, H. (2023). Dexmedetomidine attenuates myocardial ischemia–reperfusion injury in hyperlipidemic rats by inhibiting inflammation, oxidative stress and NF‐κB. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14324
Vancouver
Gao W, Du L, Li N, Li Y, Wu J, Zhang Z, et al. Dexmedetomidine attenuates myocardial ischemia–reperfusion injury in hyperlipidemic rats by inhibiting inflammation, oxidative stress and NF‐κB. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14324
BibTeX
@article{Gao2023,
author = {Gao, Weiwei and Du, Liang and Li, Nan and Li, Yating and Wu, Jinfang and Zhang, Ze and Chen, Huan},
title = {Dexmedetomidine attenuates myocardial ischemia–reperfusion injury in hyperlipidemic rats by inhibiting inflammation, oxidative stress and NF‐κB},
journal = {Chemical Biology & Drug Design},
year = {2023},
doi = {10.1111/cbdd.14324}
}
EUVIMED